Best Neurology Companies in New York City, United States
The 80 best Neurology companies in New York City, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: LEXEO Therapeutics.
Our analysis of 50 Neurology companies
$7.4b in tracked funding; 74% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Neurology companies in New York City
| # | Company | Disclosed funding | Last round | Employees | Founder | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|
| 1 | LEXEO Therapeutics Developer of gene therapy for the treatment of CLN2 Batten and Alzheimer's diseases 29Funding top 19%News top 43%Growth top 47%Tech bottom 49% All 9 signals ▾Fundingtop 19% Newstop 43% Growthtop 47% Techbottom 49% Talentbottom 40% Globalbottom 39% Marketbottom 31% Moatbottom 31% Fin. healthbottom 29% Funding: Raised $185M across 9 rounds · 9 rounds over 5 yrs (1.8/yr) News: 7 BI events in 12 mo (of 27 tracked, 4 types) · -36% YoY rank vs industry peers · Fliar Intelligence Index 29/100 | $185M | 8 mo ago | 58 58 → 97 (+67%) | Nolan Townsend CEO | — | 1 launch |
| 2 | Precision Neuroscience Developed of brain-computer interface tool for medical treatment and drug development 50Funding top 18%Moat top 31%Talent top 38%Tech top 39% All 9 signals ▾Fundingtop 18% Moattop 31% Talenttop 38% Techtop 39% AItop 45% Growthbottom 40% Globalbottom 37% Marketbottom 34% Newsbottom 18% Funding: Raised $174M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) Moat: Editorial + unicorn rating 8/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 50/100 | $174M | 7 mo ago | 22 | Benjamin Rapoport Co-Founder & CSO | — | 1 job opening · 2 launchs · 1 award |
| 3 | LB Pharmaceuticals Developer of small molecule based therapeutics for schizophrenia 67Moat top 21%Growth top 23%Patents top 25%News top 27% All 10 signals ▾Moattop 21% Growthtop 23% Patentstop 25% Newstop 27% Fundingtop 30% Innovationtop 34% Talenttop 41% Marketbottom 44% Globalbottom 43% Partnersbottom 35% Moat: Editorial + unicorn rating 7/10 · IP moat: 437 patents Growth: 1 acquisition/expansion move in 24 mo · Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 67/100 | $130M | 4 mo ago | — | Zachary Prensky Founder & CEO | 437 patents Small-molecule immunomodulators targeting CXCR4/Btk, IL-6, and complement pathways | — |
| 4 | MeiraGTx Developer of gene therapies for ocular and neurodegenerative diseases | $130M | 31 mo ago | 358 358 → 419 (+17%) | — | 14 patents Therapeutic modulation of the retromer complex for neurodegenerative disease treatment | — |
| 5 | Prevail Therapeutics Developer of gene therapies for treating neurodegenerative and rare diseases | $125M | 86 mo ago | 70 | Asa Abeliovich Founder & CEO | 227 patents Developing gene therapy vectors targeting lysosomal storage disease treatments. | — |
| 6 | MindMed Developer of psychedelic-based therapies for brain health disorders | $118M | 27 mo ago | 48 | JR Rahn Co-Founder | — | — |
| 7 | Ovid Therapeutics Developer of therapeutics for rare neurological diseases | $106M | 113 mo ago | 40 40 → 40 (+0%) | Hongxing Zhou Co-Founder & CEO | 622 patents Patents concentrated in health & consumer products | — |
| 8 | Curemark Developer of therapeutics for the treatment of Autism and other neurological diseases | $93M | 40 mo ago | 9 | — | 269 patents Neuropsychiatric disorder therapeutics and addiction treatment formulations | — |
| 9 | Leal Therapeutics Developer of therapeutics to treat neurological diseases 32Funding top 21%Moat top 42%Talent bottom 49%Market bottom 36% All 5 signals ▾Fundingtop 21% Moattop 42% Talentbottom 49% Marketbottom 36% Globalbottom 29% Funding: Raised $84.0M across 3 rounds · 3 rounds over 2 yrs (1.5/yr) Moat: Editorial + unicorn rating 4/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 32/100 | $84M | 9 mo ago | 25 | Asa Abeliovich Founder & CEO | — | — |
| 10 | Gilgamesh Developer of drugs for neuropsychiatric conditions 62Growth top 15%Funding top 17%Talent top 23%News top 28% All 9 signals ▾Growthtop 15% Fundingtop 17% Talenttop 23% Newstop 28% Moattop 39% AItop 45% Techbottom 40% Globalbottom 39% Marketbottom 21% Growth: Fresh capital in last 24 mo Funding: Raised $83.1M across 13 rounds · 13 rounds over 6 yrs (2.2/yr) rank vs industry peers · Fliar Intelligence Index 62/100 | $83M | 2 mo ago | 2 | Jonathon Sporn Co-Founder & CEO | — | — |
| 11 | Intra-Cellular Therapies Developer of therapeutics for psychiatric and neurologic diseases 78Patents top 20%Moat top 23%Funding top 26%Market top 27% All 11 signals ▾Patentstop 20% Moattop 23% Fundingtop 26% Markettop 27% Fin. healthtop 27% Innovationtop 29% Producttop 36% Growthtop 40% Techbottom 46% Globalbottom 42% Newsbottom 23% Patents: 1,493 patents matched (strict assignee match) · 508 filings since 2022 vs 551 in 2017-21 Moat: Top 11% by revenue among 18 tracked Neurology companies · Editorial + unicorn rating 6/10 rank vs industry peers · Fliar Intelligence Index 78/100 | $81M | 13 mo ago | 610 610 → 639 (+5%) | — | 1,481 patents Deuterated small‑molecule therapeutics and novel organic drug compounds | — |
| 12 | JDS Pharmaceuticals Small molecule drugs for psychiatry and women's health | $62M | 261 mo ago | — | Michael Satow Co-founder & CEO | — | — |
| 13 | Quentis Therapeutics Developer of therapies for treating cancer and neurodegenerative diseases | $51M | 90 mo ago | 4 | — | — | — |
| 14 | Cara Therapeutics Developer of therapeutics for pain relief and inflammatory diseases | $51M | 138 mo ago | 79 | Chris Posner President and CEO | 210 patents Novel oral and oligosaccharide delivery systems for kappa opioid receptor agonist therapeutics | — |
| 15 | Linus Biotechnology Developer of diagnostic tests for central nervous system and gastrointestinal disorders | $48M | 22 mo ago | 12 | Paul Curtin Co-Founder | 15 patents Molecular exposomics platforms and bio-surface topographic imaging for health monitoring | — |
| 16 | Proneuron Biotechnologies Developer of therapies for spinal cord injury and other neurological conditions | $37M | 232 mo ago | — | Dale S Miller Co-Founder | — | — |
| 17 | Magnolia Neurosciences Developer of therapies for treating neurodegenerative diseases and neuronal injuries | $31M | 94 mo ago | 1 | — | — | — |
| 18 | Seelos Therapeutics Developer of therapies for treating CNS disorders and rare diseases | $27M | 46 mo ago | 16 | Raj Mehra Founder & CEO | — | — |
| 19 | Palyon Medical Implantable Drug delivery systems for CNS disorders | $24M | 205 mo ago | — | David Present CEO | — | — |
| 20 | Remedy Pharmaceuticals Intravenous formulation for acute central nervous system conditions such as stroke (ischemic and… | $23M | 115 mo ago | 6 | — | — | — |
| 21 | Empyrean Developer of therapeutics for neuropsychiatric and neurologic diseases | $22M | 44 mo ago | 8 | Usman Azam CEO | — | — |
| 22 | Oculogica Eye tracking technology to detect traumatic brain injury (TBI) | $22M | 25 mo ago | 12 | — | 30 patents Eye‑tracking based diagnostic systems for concussion, substance use, and glaucoma detection. | 1 launch |
| 23 | Bioasis A proprietary peptide based delivery platform for developing CNS drugs which can cross the blood-brain barrier | $17M | 60 mo ago | 7 | — | 12 patents Engineered fusion protein therapeutics for lysosomal storage diseases, metastatic cancer, and BBB delivery | — |
| 24 | Intrance Medical Systems Developer of therapeutics for the treatment of Parkinson's disease | $17M | 57 mo ago | 3 | Patrick Shea CEO | — | — |
| 25 | Redpin Therapeutics Developer of cell therapies for Neurological and Psychiatric disorders | $17M | 75 mo ago | 10 | — | — | — |
| 26 | ProJenX Developer of targeted therapies to treat amyotrophic lateral sclerosis (ALS) | $15M | 15 mo ago | 4 | Stan Abel President and Chief Executive Officer | — | — |
| 27 | Anavex Developer of therapeutics for neurodegenerative diseases | $14M | 65 mo ago | 40 40 → 47 (+18%) | Christopher Missling President & CEO | — | — |
| 28 | Axsome Therapeutics Developer of therapeutic solutions for the management of CNS disorders | $13M | 89 mo ago | 545 | — | 671 patents Patents concentrated in health & consumer products | — |
| 29 | Sania Developer of gene therapies to treat neurological diseases | $12M | 25 mo ago | 5 | Rob Brownstone Co-Founder | — | — |
| 30 | Mitokinin PINK1-targeted therapies for mitochondria-associated diseases (familial form of Parkinson's Disease) | $10M | 92 mo ago | 19 | Daniel Roulet Co-Founder & CEO | 80 patents Patents concentrated in chemistry & materials | — |
| 31 | Soterix Medical Neuromodulation and brain stimulation technology for neuropsychiatric and neurological disorders | $9M | 14 mo ago | 37 | Abhishek Datta CEO & CTO | — | — |
| 32 | Oligomerix Developer of therapeutics for Alzheimer’s disease and related neurodegenerative diseases | $8M | 13 mo ago | 11 | Eliot Davidowitz Co-Founder | 55 patents Small-molecule inhibitors targeting tau oligomer formation for neurodegenerative therapeutics | — |
| 33 | Fisher Wallace Provider of portable brain-stimulating device | $6M | 46 mo ago | 15 | Kelly Roman Co-Founder & CEO | — | — |
| 34 | Tonix Pharma Developer of next-generation medicines for CNS and immunological disorders | $4M | 14 mo ago | 117 117 → 169 (+44%) | — | — | — |
| 35 | Kures Developer of opioid-based therapeutics for mood and depression disorders | $4M | 81 mo ago | — | Andrew Kruegel Co-Founder | 12 patents Novel opioid analgesic compounds and polymorphs for pain therapeutics. | — |
| 36 | Bright Cloud International Devices for neurological rehabilitation therapy | $4M | 81 mo ago | — | Grigore Burdea Founder and Chief Technology Officer | — | — |
| 37 | Corino Therapeutics Company developing rare disease treatments | $3M | 110 mo ago | — | Michael Roberts CEO | — | — |
| 38 | Lime Therapeutics Developer of therapeutics for cancer, metabolic diseases, and neurodegenerative disorders | $3M | 26 mo ago | 2 | Daniel Heller Co-Founder | — | — |
| 39 | Protagenic Develops neuropeptides for the treatment of anxiety and depression based mood disorders | $3M | 69 mo ago | 2 | — | — | — |
| 40 | Ausanil Migraine and cluster headach therapeutics | $2M | 141 mo ago | 2 | — | — | — |
| 41 | Mercia Pharma Vaccine in combination with adjuvants for autoimmune, CNS, respiratory and infectious diseases | $2M | 203 mo ago | — | Peter Blackburn President and Founder | — | — |
| 42 | Lauren Sciences They develop nanomedicines for central nervous system diseases | $600K | 46 mo ago | — | Susan Rosenbaum Founder & CEO | — | — |
| 43 | Cerespir Immuno-neurology company developing novel treatments for neurodegenerative diseases | $500K | 117 mo ago | 5 | — | 17 patents Pharmaceutical co-crystal polymorphs for improved drug formulation and delivery. | — |
| 44 | Akelos Biotechnology firm pioneering non-opioid neuropathic pain treatments | $320K | 3 mo ago | 4 | Steven Fox Founder | — | — |
| 45 | Innovation1 Biotech Developer of psychedelic and cannabinoid-based drugs for neurological disorders | $300K | 42 mo ago | — | Jeffrey Kraws CEO | — | — |
| 46 | Oxygen Therapy Early Stage biopharma company developing anti-necrosis drugs for conditions resulting from Ischemia | $300K | 118 mo ago | — | Yuval Kwintner Founder | — | — |
| 47 | Avenue Therapeutics Neurologic disease specialty pharmaceutical company developing impactful therapies for unmet needs | $200K | 40 mo ago | 2 | — | — | — |
| 48 | ADispell Preclinical biotech company developing small molecule therapeutics for Alzheimers, Parkinsons and other… | $171K | 181 mo ago | — | Stephen Curry Co-Founder & CEO | 6 patents Pharmaceutical therapies for addiction, anxiety, and cognitive modulation | — |
| 49 | Autism Diagnostic Technology Brain mapping technology for autism, dyslexia and Alzheimer's disease | $170K | 33 mo ago | 3 | Andrew Stewart CEO | — | — |
Top 12 Neurology companies in New York City
#1
Series B · New York City, New York · founded 2019 · 2 employees$83.1Mraised▾
Developer of drugs for neuropsychiatric conditions. The company has an AI-powered discovery and translational platform to develop novel psychotropic drugs for the treatment of neuropsychiatric conditions including depression, anxiety, substance use, and stress-related disorders. Products include GM-1020 and GM-2505 an oral NMDAR Antagonist.
- Mar 2026Series B$2.2M
- Mar 2026Series B$60M
- Jan 2026Series B$6.1M
- May 2025Grant (prize money)$5.4M
#2
Public · New York City, New York · founded 2015$130.1Mraised▾
Developer of small molecule based therapeutics for schizophrenia. The company's lead product candidate LB-102, also known as N-methyl amisulpride, is very similar to the marketed antipsychotic amisulpride and differs by only one methyl group (CH3). The drug acts as an antagonist to dopamine (D2, D3), and 5-HT7 receptors and exerts the antipsychotic effect.
- Feb 2026Post IPO$100M
- Aug 2023Series C$110.7M
- Aug 2020Series B$10M
- Mar 2019Series A$1.6M
#3
Public · New York City, New York · founded 2018 · 58 employees$185Mraised▾
Developer of gene therapy for the treatment of CLN2 Batten and Alzheimer's diseases. It has developed a lead candidate LX1001 APOE4 inhibitor that helps in treating Alzheimer’s andother neurological disorders. Its drug candidate LX2006 cardiomyopathy helps in the treatment of Friedreich’s Ataxia & other genetic disorders. It also provides LX1004 CLN2 drug that plays an important role in treating Batten disease.
- Oct 2025Post IPO$10M
- May 2025Post IPO$80M
- Mar 2024Post IPO$95M
- Aug 2023Series B—
#4
Series C · New York City, New York · founded 2021 · 22 employees$173.8Mraised▾
Developed of brain-computer interface tool for medical treatment and drug development. The company has developed a next-generation brain computing technology that has the ability to process medicine and computing. The brain implants have features for AI-based computing, device integration, and assessment of neurological illness for medicine development.
- Nov 2025Series C—
- Jan 2025Series C—
- Oct 2024Series C$102M
- Mar 2024Series B$27.5M
#5
Series A · New York City, New York · founded 2021 · 25 employees$84Mraised▾
Developer of therapeutics to treat neurological diseases. The company is advancing precision therapeutics for genetic targets to address severe CNS disorders.
- Aug 2025Series A$30M
- Oct 2024Series A$45M
- Feb 2024Seed$39M
#6
Acquired · New York City, New York · founded 2002 · 610 employees$80.9Mraised▾
Developer of therapeutics for psychiatric and neurologic diseases. The company’s product, ITI-007 is a novel first-in-class 5-HT2A antagonist, Dopamine receptor phosphoprotein modulator (DPPM) designed to treat multiple deficits in patients with schizophrenia while lacking the side-effects of existing antipsychotic drugs. It also developed a state of the art technology platform, called CNSProfil that is capable of generating a unique molecular signature for drug compounds.
- Apr 2025Grant (prize money)$6.2M
- Jan 2025Grant (prize money)$6.2M
- Jul 2014Grant (prize money)$318.9K
- Aug 2013Series C$60M
#7
Series B · New York City, New York · founded 2006 · 11 employees$7.9Mraised▾
Developer of therapeutics for Alzheimer’s disease and related neurodegenerative diseases . It has developed two approaches for small molecule drug discovery tau oligomer inhibitor program and tau protease inhibitor program. Its drugs target neurotoxic tau oligomers that impair learning and memory and that cause spread of Alzheimer’s and related neurodegenerative diseases in the brain.
- May 2025Grant (prize money)$4.6M
- Nov 2024Conventional Debt$75K
- Sep 2022Grant (prize money)$2.5M
- Aug 2022Grant (prize money)$3.4M
#8
Series A · New York City, New York · founded 2020 · 12 employees$47.6Mraised▾
Developer of diagnostic tests for central nervous system and gastrointestinal disorders. The company offers StrandDx ASD, a non-invasive diagnostic aid for Autism Spectrum Disorder. The company's pipeline comprises precision exposome medicine biomarkers and target discovery across gastroenterology, renal disease and oncology.
- Jul 2024Series A$6.1M
- May 2023Series A$8M
- Jan 2023Series A$16M
- Mar 2022Series A$17.5M
#9
Series A · New York City, New York · founded 2021 · 4 employees$15Mraised▾
Developer of targeted therapies to treat amyotrophic lateral sclerosis (ALS). The lead therapeutic candidate "Prosetin", is an oral, brain-penetrant, MAP4 kinase inhibitor targeting endoplasmic reticulum (ER) stress-mediated motor neuron death for the treatment of people with Amyotrophic lateral sclerosis (ALS).
- Mar 2025Grant (prize money)$2.2M
- Nov 2023Series A$15M
- Seed—
#10
Funding Raised · New York City, New York · founded 2008 · 37 employees$8.5Mraised▾
Neuromodulation and brain stimulation technology for neuropsychiatric and neurological disorders. It pioneers innovative medical treatments using non-invasive neuromodulation and integrated brain monitoring technology. The company develops and deploys solutions for clinical trials, offering unique and adaptable systems for clinicians and patients. Their portfolio includes transcranial Direct Current Stimulation (tDCS), High-Definition tDCS (HD-tDCS), Limited Total Energy tDCS (LTE-tDCS), and Neurotargeting. They distribute synergistic technologies and provide services in image analysis, modeling, and human factors. The company is committed to bringing advanced medical technology to those who need it, focusing on research systems, clinical systems, software, and pre-clinical support. They offer platforms for tDCS, tES, Transcranial Magnetic Stimulation (TMS), Transcranial Focused Ultrasound Stimulation (tFUS), functional Near Infrared Spectroscopy (fNIRS), and mobile EEG, supported by software for neurotargeting and modeling services.
- Mar 2025Grant (prize money)$956.9K
- Sep 2021Grant (prize money)$956.9K
- Aug 2021Grant (prize money)—
- Jun 2016Grant (prize money)$2.5M
#11
Seed · New York City, New York · founded 2018 · 4 employees$320Kraised▾
Biotechnology firm pioneering non-opioid neuropathic pain treatments, a biopharmaceutical company focused on translating innovative science into novel treatments for neuropathic pain. The company is developing non-narcotic drugs targeting the HCN1 ion channel to address unmet needs in chronic pain management. Their research, supported by NIH grants, focuses on creating safe and effective pain relief alternatives to opioids. They have licensed patents for novel compounds and are advancing a lead molecule through preclinical development, aiming for first-in-human studies. The company has assembled an executive team and Scientific Advisory Board of academic and business leaders to support their research. They are committed to changing modern medicine by providing life-changing care in the neuropathic pain market.
- Mar 2026Seed$1.5M
- Sep 2022Grant (prize money)$698.8K
- Oct 2019Grant (prize money)—
- Feb 2019Seed$25K
#12
Public · New York City, New York · founded 2019 · 48 employees$118Mraised▾
Developer of psychedelic-based therapies for brain health disorders. It develops product candidates to treat conditions such as generalized anxiety disorder, major depressive disorder, and autism spectrum disorder. The company utilizes rigorous scientific methods and focuses on addressing unmet patient needs in these therapeutic areas. Research and development efforts encompass diverse therapeutic areas and mechanisms of action.
- Mar 2024Post IPO$75M
- Aug 2023Post IPO$7M
- Mar 2021Post IPO$15.4M
- Jan 2021Post IPO$499.6K
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Neurology coverage by sub-theme.
Regulatory-risk over time falling
Funding & growth over time
funding falling · growth flat
How research on Neuroscience & Neurotech is moving in the United States
A read on the academic research around Neuroscience & Neurotech — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 8,477 United States-affiliated papers.
- Neurological Surgery622
- Harvard University448
- University of Florida313
- University of California, San Francisco267
- Emory University266
- Deep brain stimulation180→297
- Neuromodulation38→144
- Stimulation97→176
- Brain stimulation19→78
- Neurostimulation54→105
- Deep brain stimulation859→1079
- Neuromodulation95→285
- Neurostimulation157→315
- Stimulation383→535
- Epilepsy60→211
- Neurostimulation45→123
- Neuromodulation41→110
- Epilepsy21→60
- Transcranial magnetic stimulation17→38
- Chronic pain3→23
Where neurotech is researched across United States
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing neurotech patents in the United States
United States neurotech patent filing is accelerating — 2,059 filings from 781 assignees (2016–2025), led by Boston Scient Neuromodulation, Medtronic, Advanced Neuromodulation Systems; annual filings 205→349.
- Boston Scient Neuromodulation865
- Medtronic277
- Advanced Neuromodulation Systems124
- Cardiac Pacemakers75
- Pacesetter67
- Cyberonics54
- PREC Neuroscience43
- Axonics43
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.